Beyond steroids: clinical outcomes of intralesional low molecular weight heparin in the management of oral lichen planus: a case series

Simran Jeet Sindhu; Swati Gupta; K. Nagaraju; Sangeeta Malik; Supriya Singh; Aarti Talwar; Komal Chaudhary

doi:10.18203/2319-2003.ijbcp20254164

Authors

Simran Jeet Sindhu Department of Oral Medicine and Radiology, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India
Swati Gupta Department of Oral Medicine and Radiology, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India
K. Nagaraju Department of Oral Medicine and Radiology, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India
Sangeeta Malik Department of Oral Medicine and Radiology, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India
Supriya Singh Department of Oral Medicine and Radiology, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India
Aarti Talwar Department of Oral Medicine and Radiology, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India
Komal Chaudhary Dr. Goel’s Dental and maxillofacial clinic, Hapur, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20254164

Keywords:

Oral lichen planus, Intralesional injection, Low molecular weight heparin, Enoxaparin, Mucosal lesions

Abstract

The objective was to assess the clinical efficacy and safety of intralesional enoxaparin in symptomatic oral Lichen planus (OLP) management, coupled with a review of the literature. Ten patients with clinically and histopathologically diagnosed OLP were enrolled and treated with intralesional injections of enoxaparin (3 mg/ml) weekly for a period of eight weeks. Clinical parameters assessed were lesion type, pain according to the visual analogue scale (VAS), lesion severity according to the T-score, and quality of life (QoL) at both the initial visit and follow-up. Of the 10 patients included, the mean age was 40.0±17.78 years, with 60% female distribution, presenting most with erosive and reticular lesions in equal proportions. Outcomes revealed significant symptomatic improvement and clinical resolution, as highlighted by a sharp drop in VAS scores from 8.0 to 0.0, a drop in T-scores from 3.6 to 0.67, and an increase in QoL scores from 4.4 to 10.0, indicating complete resolution in daily functioning; there were no reported side effects. Weekly intralesional injections of enoxaparin are safe and represent an effective treatment modality in symptomatic OLP, improving pain symptoms, leading to resolution of lesions, and enhancing the QoL.

Metrics

Metrics Loading ...

References

Sharma S, Kamarthi N, Goel S, Malik S, Gupta S, Sharma A. Comparative evaluation of autologous platelet-rich plasma and triamcinolone acetonide injection in the management of erosive lichen planus and oral submucous fibrosis: a clinical study. Int J Basic Clin Pharmacol. 2023;12(3):439-45. DOI: https://doi.org/10.18203/2319-2003.ijbcp20231125

Mahesh D, Nancy R, Chaya M David. Enoxaparin in the management of lichen planus: a review. Int J Sci Res. 2021;10(1):23.

Gajula N, Kalikota A, Rohit V, Shakeer H. Comparative evaluation of oral corticosteroids versus low molecular weight heparin in the treatment of lichen planus. Int J Res Dermatol. 2019;5(2):307-13. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20191557

Solak B. Low-molecular-weight heparins as immunomodulators in dermatology practice. Am J Ther. 2016;23(6):e1911-7. DOI: https://doi.org/10.1097/MJT.0000000000000251

Lunge S, Patil S, Manjunathswamy B. A comparative study of methotrexate and low molecular weight heparin for the treatment of generalized lichen planus. Indian J Clin Exp Dermatol. 2016;2:153-8.

Neville JA, Hancox JG, Williford PM, Yosipovitch G. Treatment of severe cutaneous ulcerative lichen planus with low molecular weight heparin in a patient with hepatitis C. Cutis. 2007;79(1):37.

Kerdel HP. Successful treatment of lichen planus with low-molecular-weight heparin: a case series of seven patients. J Dermatolog Treat. 2001;12(2):123-6. DOI: https://doi.org/10.1080/095466301317085444

Parlapalli N, Priscilla T. Effective treatment option for lichen planus: steroids or low molecular weight heparins? Indian J Drugs Dermatol. 2021;7(2):60-6. DOI: https://doi.org/10.4103/ijdd.ijdd_31_20

Tian K, Abbas K, Andres R, Kobric D, Sussman G. Low molecular weight heparin: a novel option for treatment refractory chronic spontaneous urticaria. J Allergy Clin Immunol. 2020;145(2):AB201. DOI: https://doi.org/10.1016/j.jaci.2019.12.303

Hodak E, Yosipovitch G, David M, Ingber A, Chorev L, Lider O, et al. Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report. J Am Acad Dermatol. 1998;38(4):564-8. DOI: https://doi.org/10.1016/S0190-9622(98)70118-5

Iraji F, Asilian A, Saeidi A, Siadat AH, Saeidi AR, Hassanzadeh A. Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of lichen planus: a clinical trial. Adv Biomed Res. 2013;2(1):76. DOI: https://doi.org/10.4103/2277-9175.115798

Ghaffari S, Barikbin L, Ashnagar S, Hajji Fattahi F, Tavakoli Kia R, Rezaiee M. Enoxaparin for the treatment of recurrent aphthous stomatitis: a pilot exploratory clinical trial. Minerva Stomatol. 2013;62(7-8):281-7.